JP2016501222A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501222A5 JP2016501222A5 JP2015545170A JP2015545170A JP2016501222A5 JP 2016501222 A5 JP2016501222 A5 JP 2016501222A5 JP 2015545170 A JP2015545170 A JP 2015545170A JP 2015545170 A JP2015545170 A JP 2015545170A JP 2016501222 A5 JP2016501222 A5 JP 2016501222A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pharmaceutical combination
- pharmaceutically acceptable
- inhibitor compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731174P | 2012-11-29 | 2012-11-29 | |
| US61/731,174 | 2012-11-29 | ||
| US201261731555P | 2012-11-30 | 2012-11-30 | |
| US61/731,555 | 2012-11-30 | ||
| US201361755520P | 2013-01-23 | 2013-01-23 | |
| US61/755,520 | 2013-01-23 | ||
| PCT/US2013/071852 WO2014085381A1 (en) | 2012-11-29 | 2013-11-26 | Pharmaceutical combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501222A JP2016501222A (ja) | 2016-01-18 |
| JP2016501222A5 true JP2016501222A5 (cg-RX-API-DMAC7.html) | 2017-01-12 |
| JP6437444B2 JP6437444B2 (ja) | 2018-12-12 |
Family
ID=49753513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545170A Active JP6437444B2 (ja) | 2012-11-29 | 2013-11-26 | 医薬的組合せ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9446043B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2925366B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6437444B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104812415A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013352379B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015012497B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2892578C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2925366T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2669248T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE037618T2 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ708802A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2925366T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2674995C2 (cg-RX-API-DMAC7.html) |
| TR (1) | TR201806682T4 (cg-RX-API-DMAC7.html) |
| UA (1) | UA115250C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014085381A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201904851D0 (en) | 2019-04-05 | 2019-05-22 | Katholieke Univ Leven | Melanoma treatment |
| US11086278B2 (en) | 2019-08-29 | 2021-08-10 | Inventus Holdings, Llc | Adaptive system monitoring using incremental regression model development |
| US20240207257A1 (en) * | 2021-04-15 | 2024-06-27 | Ideaya Biosciences, Inc. | Combination therapy comprising a pkc inhibitor and a mek inhibitor |
| WO2024044774A2 (en) * | 2022-08-26 | 2024-02-29 | Ideaya Biosciences, Inc. | Methods of treating uveal melanoma with a pkc inhibitor |
| GB202408599D0 (en) * | 2024-06-14 | 2024-07-31 | Vasopharma Ab | Combination treatments |
| GB202408598D0 (en) * | 2024-06-14 | 2024-07-31 | Edvince Ab | Combination treatments |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489608A (en) | 1989-12-21 | 1996-02-06 | Goedecke Aktiengesellschaft | Indolocarbazole derivatives and the use thereof |
| US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| PE49195A1 (es) | 1993-12-07 | 1996-01-06 | Lilly Co Eli | Inhibidor de proteinquinasa |
| US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
| EP1449529B1 (en) | 1993-12-23 | 2010-01-27 | Eli Lilly And Company | Protein Kinase C Inhibitors |
| ZA969646B (en) | 1995-11-20 | 1998-05-18 | Lilly Co Eli | Protein kinase C inhibitor. |
| YU2503A (sh) | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
| US6645970B2 (en) | 2000-11-07 | 2003-11-11 | Novartis Ag | Indolylmaleimide derivatives |
| DE60140201D1 (en) | 2000-11-07 | 2009-11-26 | Novartis Ag | Indolylmaleimidderivative als proteinkinase-c-inhibitoren |
| TWI350285B (en) | 2002-03-13 | 2011-10-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
| RS50569B (sr) | 2004-06-11 | 2010-05-07 | Japan Tobacco Inc. | Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka |
| EP2361905B1 (en) | 2005-05-18 | 2013-03-06 | Array Biopharma Inc. | Heterocyclic Inhibitors of MEK and methods of use thereof |
| MX2008000463A (es) | 2005-07-11 | 2008-03-11 | Novartis Ag | Derivados de indolil-maleimida. |
-
2013
- 2013-11-26 TR TR2018/06682T patent/TR201806682T4/tr unknown
- 2013-11-26 PL PL13802815T patent/PL2925366T3/pl unknown
- 2013-11-26 AU AU2013352379A patent/AU2013352379B2/en active Active
- 2013-11-26 BR BR112015012497-6A patent/BR112015012497B1/pt active IP Right Grant
- 2013-11-26 EP EP13802815.4A patent/EP2925366B1/en active Active
- 2013-11-26 HU HUE13802815A patent/HUE037618T2/hu unknown
- 2013-11-26 RU RU2015124954A patent/RU2674995C2/ru active
- 2013-11-26 UA UAA201505167A patent/UA115250C2/uk unknown
- 2013-11-26 DK DK13802815.4T patent/DK2925366T3/en active
- 2013-11-26 NZ NZ70880213A patent/NZ708802A/en unknown
- 2013-11-26 WO PCT/US2013/071852 patent/WO2014085381A1/en not_active Ceased
- 2013-11-26 JP JP2015545170A patent/JP6437444B2/ja active Active
- 2013-11-26 US US14/647,939 patent/US9446043B2/en active Active
- 2013-11-26 CN CN201380061889.8A patent/CN104812415A/zh active Pending
- 2013-11-26 CA CA2892578A patent/CA2892578C/en active Active
- 2013-11-26 ES ES13802815.4T patent/ES2669248T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501222A5 (cg-RX-API-DMAC7.html) | ||
| Manic et al. | Chloroquine and hydroxychloroquine for cancer therapy | |
| Kim et al. | A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer | |
| KR102418765B1 (ko) | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 | |
| Bullard Dunn et al. | Evolving therapies and FAK inhibitors for the treatment of cancer | |
| JP2017502017A5 (cg-RX-API-DMAC7.html) | ||
| JP2015523397A5 (cg-RX-API-DMAC7.html) | ||
| JP2018109022A5 (cg-RX-API-DMAC7.html) | ||
| BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| JP2014525454A5 (cg-RX-API-DMAC7.html) | ||
| JP2015526410A5 (cg-RX-API-DMAC7.html) | ||
| JP2014509657A5 (cg-RX-API-DMAC7.html) | ||
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| JP2006512324A5 (cg-RX-API-DMAC7.html) | ||
| RU2015124954A (ru) | Фармацевтические комбинации | |
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| JP2012236857A5 (cg-RX-API-DMAC7.html) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| JP2022544485A (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| WO2019058348A1 (en) | COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER | |
| JP2019528302A5 (cg-RX-API-DMAC7.html) | ||
| CA2835717A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |